Applied Therapeutics, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • APLT
  • 1d-1.94%
  • 1w-9.16%
  • 1m-15.95%
  • 1y505.26%
ATH
  • ATH Price$55.47
  • ATH Date2020-02-05
  • % since ATH-90.88%
  • % to ATH996.25%
ATL
  • ATL Price$0.54
  • ATL Date2022-10-12
  • % from ATL837.04%
  • Last Low Price$0.54
  • Last Low Date2022-10-12
  • % From Last Low837.04%
IPO
  • IPO Price$8.40
  • % Current ROI USD-39.76%
  • ATH Price$55.47
  • % ROI ATH 1,027,222.22%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="APLT"]

Key Data [addtoany]

Current price $5.06
Sector Healthcare
Industry Biotechnology
Today's High/Low $5.26/$4.92
Volume 1,098,498.00
Previous Close $5.16
52 Week High/Low $9.39/$0.88
Market Cap 546,376,896.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.39
Annualized Dividend $0
$5.06
[addtoany]

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.
Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.
The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.
Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity